Fig. 5.
Fig. 5. Adriamycin toxicity in U937 and TUR cells with inhibited PARP by 3-ABA or depleted PARP by asPARP transfectants. / (A) Adriamycin toxicity as the percentage of remaining viable U937 and TUR cells after a 24-hour incubation with 10−8 M to 10−5 M adriamycin in the absence (▪) or presence (●) of 1 mM 3-ABA and 2 μM MG-132 (▴), respectively. Moreover, stable transfectants of U937 and TUR cells containing a functional asPARP expression vector (asPARP cells, ▾) were also examined with respect to the adriamycin-induced cytotoxicity, respectively. (B) Western blot control of PARP protein expression in the constitutively functional asPARP vector of stably transfected U937 cells (U937 asPARP) and TUR cells (TUR asPARP), respectively, without impairment of proteasome protein levels. The actin immunoblot demonstrated equal loading.

Adriamycin toxicity in U937 and TUR cells with inhibited PARP by 3-ABA or depleted PARP by asPARP transfectants.

(A) Adriamycin toxicity as the percentage of remaining viable U937 and TUR cells after a 24-hour incubation with 10−8 M to 10−5 M adriamycin in the absence (▪) or presence (●) of 1 mM 3-ABA and 2 μM MG-132 (▴), respectively. Moreover, stable transfectants of U937 and TUR cells containing a functional asPARP expression vector (asPARP cells, ▾) were also examined with respect to the adriamycin-induced cytotoxicity, respectively. (B) Western blot control of PARP protein expression in the constitutively functional asPARP vector of stably transfected U937 cells (U937 asPARP) and TUR cells (TUR asPARP), respectively, without impairment of proteasome protein levels. The actin immunoblot demonstrated equal loading.

Close Modal

or Create an Account

Close Modal
Close Modal